Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters

被引:115
|
作者
Shen, Chen-Hsiang [1 ]
Wang, Yuan-Fang [1 ]
Kovalevsky, Andrey Y. [1 ]
Harrison, Robert W. [1 ,2 ]
Weber, Irene T. [1 ,3 ]
机构
[1] Georgia State Univ, Dept Biol, Mol Basis Dis Program, Atlanta, GA 30302 USA
[2] Georgia State Univ, Dept Comp Sci, Mol Basis Dis Program, Atlanta, GA 30302 USA
[3] Georgia State Univ, Dept Chem, Mol Basis Dis Program, Atlanta, GA 30302 USA
基金
美国国家卫生研究院;
关键词
aspartic protease; conformational change; enzyme inhibition; HIV; AIDS; X-ray crystallography; RESOLUTION CRYSTAL-STRUCTURES; INHIBITOR; POTENT; MUTATIONS; BINDING; SAQUINAVIR; MECHANISMS; NONPEPTIDE; STABILITY; SUBSTRATE;
D O I
10.1111/j.1742-4658.2010.07771.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The structural and kinetic effects of amprenavir (APV), a clinical HIV protease (PR) inhibitor, were analyzed with wild-type enzyme and mutants with single substitutions of V32I, I50V, I54V, I54M, I84V and L90M that are common in drug resistance. Crystal structures of the APV complexes at resolutions of 1.02-1.85 angstrom reveal the structural changes due to the mutations. Substitution of the larger side chains in PRV32I, PRI54M and PRL90M resulted in the formation of new hydrophobic contacts with flap residues, residues 79 and 80, and Asp25, respectively. Mutation to smaller side chains eliminated hydrophobic interactions in the PRI50V and PRI54V structures. The PRI84V-APV complex had lost hydrophobic contacts with APV, the PRV32I-APV complex showed increased hydrophobic contacts within the hydrophobic cluster and the PRI50V complex had weaker polar and hydrophobic interactions with APV. The observed structural changes in PRI84V-APV, PRV32I-APV and PRI50V-APV were related to their reduced inhibition by APV of six-, 10- and 30-fold, respectively, relative to wildtype PR. The APV complexes were compared with the corresponding saquinavir complexes. The PR dimers had distinct rearrangements of the flaps and 80's loops that adapt to the different P1' groups of the inhibitors, while maintaining contacts within the hydrophobic cluster. These small changes in the loops and weak internal interactions produce the different patterns of resistant mutations for the two drugs.
引用
收藏
页码:3699 / 3714
页数:16
相关论文
共 50 条
  • [41] Predicting drug-resistant mutations of HIV protease
    Ishikita, Hiroshi
    Warshel, Arieh
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2008, 47 (04) : 697 - 700
  • [42] Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection
    Metzner, Karin J.
    Scherrer, Alexandra U.
    Preiswerk, Benjamin
    Joos, Beda
    von Wyl, Viktor
    Leemann, Christine
    Rieder, Philip
    Braun, Dominique
    Grube, Christina
    Kuster, Herbert
    Boeni, Juerg
    Yerly, Sabine
    Klimkait, Thomas
    Aubert, Vincent
    Furrer, Hansjakob
    Battegay, Manuel
    Vernazza, Pietro L.
    Cavassini, Matthias
    Calmy, Alexandra
    Bernasconi, Enos
    Weber, Rainer
    Guenthard, Huldrych F.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (07): : 1102 - 1112
  • [43] Multiple drug resistant mechanisms against darunavir, amprenavir, and nelfinavir of HIV-1 PR
    Liu, Xiaoqing
    Dai, Qi
    Xiu, Zhilong
    JOURNAL OF MOLECULAR STRUCTURE, 2013, 1033 : 227 - 235
  • [44] Amprenavir - A protease inhibitor for the treatment of patients with HIV-1 infection
    Reddy, P
    Ross, J
    FORMULARY, 1999, 34 (07) : 567 - +
  • [45] Exploring novel HIV-1 reverse transcriptase inhibitors with drug-resistant mutants: A double mutant surprise
    Hollander, Klarissa
    Chan, Albert H.
    Frey, Kathleen M.
    Hunker, Olivia
    Ippolito, Joseph A.
    Spasov, Krasimir A.
    Yeh, Yang-Hui J.
    Jorgensen, William L.
    Ho, Ya-Chi
    Anderson, Karen S.
    PROTEIN SCIENCE, 2023, 32 (12)
  • [46] KINETIC-ANALYSIS OF MUTANT HIV-1 PROTEINASES - FUNCTIONAL-ANALYSIS OF DRUG-RESISTANT MUTANTS
    DUNN, BM
    LEELAMANIT, W
    RATERMAN, D
    LIN, YZ
    LIN, XL
    TANG, J
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 129 - 129
  • [47] Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants
    Marinello, Jessica
    Marchand, Christophe
    Mott, Bryan T.
    Bain, Anjali
    Thomas, Craig J.
    Pommier, Yves
    BIOCHEMISTRY, 2008, 47 (36) : 9345 - 9354
  • [48] Structural mechanisms of drug resistance for HIV-1 protease mutants.
    Erickson, JW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 56 - COMP
  • [49] Structural mechanisms of drug resistance for HIV-1 protease mutants.
    Erickson, JW
    FASEB JOURNAL, 1997, 11 (09): : A856 - A856
  • [50] Sexual transmission of an extensively drug-resistant HIV-1 strain
    Raymond, Stephanie
    Piffaut, Marie
    Bigot, Jonathan
    Cazabat, Michelle
    Montes, Brigitte
    Bertrand, Kevin
    Martin-Blondel, Guillaume
    Izopet, Jacques
    Delobel, Pierre
    LANCET HIV, 2020, 7 (08): : E529 - E530